Accelerated Approvals: How Recent Decisions will Impact Biotech's Future
Debate Sparked Over Recent Rulings, but What's Changed?
After 17 years of smooth sailing Iressa (gefitinib, AstraZeneca plc) notwithstanding the FDA's accelerated approval process seems to have hit some choppy waters.
To continue reading subscribe now to BioWorld Insight
Learn More about BioWorld Insight
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.